Triple-negative breast cancer (TNBC), characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) expression, accounts for approximately 15% of all breast cancers (Ferlay et al., 2021; Wang et al., 2021). The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.